Management and Board

MetrioPharm AG

Thomas Christély – Chief Executive Officer (CEO)

• Substantial collaborations and licensing agreements with major international pharma and biotech companies
• Multiple financing transactions including a reverse IPO at the Alternative Investment Market (AIM) of the London Stock Exchange
• 2019-2021 Development and sale of the German pharma start-up MYR GmbH to Gilead Sciences Inc. for €1.15 billion plus a milestone payment of a further €300 million

Thomas Christély has more than 30 years of experience in general management, finance, corporate & business development at board level - thereof more than 25 years with private and listed biotech and pharmaceutical companies in Europe and the U.S. As CEO of MetrioPharm he focuses on corporate & business development and financing.

Wolfgang Brysch, MD - Founder and Chief Scientific Officer (CSO)

• Co-founder, entrepreneur, physician
• Senior positions at Athenion, BioMedion, Antisense Pharma, Biognostik
• Scientific experience at the Max-Planck-Institute and as Chief Scientific Officer, especially in drug development

Dr. Wolfgang Brysch was chairman of the Board of Directors of MetrioPharm AG, until he moved to the position of Chief Executive Officer in 2016 and Chief Scientific Officer from 2021. Until 2014, he was managing director of BioMedion - a successful IT company, specialising in the pharmaceutical industry. Prior to this, he worked as managing director and Chief Scientific Officer at Biognostik GmbH. During that time, Dr. Brysch was also responsible for the preclinical development of various antisense cancer drugs at Antisense Pharma. Until 1992, Dr. Brysch headed a research group for molecular neurobiology and cancer research at the Max-Planck-Institute Göttingen.

Rudolf Stäger – Founder, Chairman of the Board

• Longstanding, international experience in banking management and consultancy business
• Other Board positions include Glarner Kantonalbank AG, Athenion AG and Werco Trade AG

Rudolf Stäger performs as an independent management consultant and professional Board member and focuses his activities primarily on advising small and mediumsized companies. Until 2007, Rudolf Stäger was an active bank manager and member of the executive Boards of Schroder & Co Bank AG, Vontobel Bank AG, and Luzerner Kantonalbank. After a bank apprenticeship and numerous further training courses, he gained over eight years of experience in the financial centres of Luxembourg and London, among others. During his active banking career, he was able to build on his board experience in numerous different industries. Rudolf Stäger has been Chairman of the Board of Directors since 2017 and was elected to the Board of Directors of MetrioPharm AG for a further three years at the 18th Annual General Meeting on June 27, 2024.

Ekkehard Brysch - Founder, Non-executive Member of the Board

• Co-founder, management consultant, representing the founders within the Board
• Longstanding experience in strategic management of international and cross-industry companies

Ekkehard Brysch is Managing Director of Athenion GmbH and a member of the Board of Directors of Athenion AG. From 2001 to 2014, Ekkehard Brysch was also Managing Partner of BioMedion GmbH, a company specializing in electronic data management solutions for the pharmaceutical industry. From 1980 to 2001, Ekkehard Brysch was managing director and partner of a BDU consulting company. Ekkehard Brysch was elected to the Board of Directors of MetrioPharm AG for a further three years at the 18th Annual General Meeting on June 27, 2024.

Werner Wolf, PhD - Non-executive Member of the Board

Dr. Werner Wolf is a strategy consultant for start-ups, and a consultant for international institutions. From 1974 to 1998, he worked for Boehringer Mannheim (later Roche) as head of global development of Biochemica. Until 2008 he was senior venture partner and science & technology advisor for TVMCapital in Munich and Boston. Dr. Wolf assumed several Supervisory Board mandates, also as a chairman. He was elected to the Board of Directors of MetrioPharm AG for a further three years at the 16th Annual General Meeting on June 23rd, 2022.

Markus Wenner - Non-executive Member of the Board

Markus Wenner is managing partner of GCI Management Consulting GmbH. Prior to that engagement, he worked for GSM Industries as an investment manager. He also held a position as a lawyer for the international business law firm Clifford Chance in the fields of mergers/acquisitions and corporate finance. Markus Wenner is currently holding further Board positions at Ringmetall, Traumhaus, aifinyo, Wolftank Adisa Holding, and others. Mr. Wenner was elected to the Board of Directors of MetrioPharm AG for further three years at the 16th Annual General Meeting on June 23rd, 2022.

Jörg Gruber - Non-executive Member of the Board

Jörg Gruber is Chairman of the venture capital and corporate finance boutique Clubb Capital Limited in London and has been assisting emerging biotechnology companies since the early 1990s. His past clients include BioMarin, YM BioSciences and Raptor Pharmaceuticals. Prior to his career in venture capital, he was a banker and investment banker with UBS, Goldman Sachs and Lehman Brothers. He is Chairman of Constant Therapeutics LLC and advisor to Eisbach Bio GmbH. Previously, he served on the board of FORBIUS (Formation Biologics Inc.) until the latter's acquisition by Bristol Myers in the fall of 2020. He has been advising MetrioPharm since 2009 and was confirmed as a member of the Board of Directors of MetrioPharm AG for a further three years at the 18th Annual General Meeting on June 27, 2024.

Christoph von Moos - Non-executive Member of the Board

Christoph von Moos is Managing Director Senior Advisor at Bank Vontobel AG. He has held management and executive positions at various banks. He advises clients on all financial matters and also assists them with private equity investments. Christoph von Moos was elected to the Board of Directors of MetrioPharm AG for a further three years at the 17th Annual General Meeting on June 20th, 2023.